Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2017

06.11.2017 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM

verfasst von: Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Jean-Jacques Kiladjian, Ruben Mesa, Michael A. Thompson

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The use of social media has now become a standard means of communication for many individuals worldwide. The use of one specific form of social media, Twitter, has increased among healthcare providers, both as a means of information gathering and as a conduit for original content creation. Recently, major efforts by users have been put forward to help streamline the unprecedented amount of information that can be found on Twitter. These efforts have led to the creation of diseasespecific hashtag (#) medical communities and have greatly enhanced the ability to understand and better categorize the available data on Twitter. Specifically, for those involved in rare cancer fields, adhering to organically designed and consistently used hashtags has led to the rapid, reliable dissemination of information and the ability to efficiently discuss and debate topics of interest in the field. For the field of myeloproliferative neoplasms (MPNs), the creation of #MPNSM (myeloproliferative neoplasms on social media) in 2015 has facilitated interactions among healthcare stakeholders from all over the world in the MPN field.

Recent findings

In order to better understand the trends and topics of interest to Twitter users of this novel medical community, we conducted the present analysis which focuses on Twitter analytics from the first two years of #MPNSM.

Summary

In this analysis, we observed a sustained increase in the number of Twitter users, number of tweets, number of impressions, and number of retweets over time, demonstrating the feasibility of creating and maintaining a disease-specific hashtag for a rare cancer over time.
Literatur
4.
Zurück zum Zitat Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: Twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10:405–12.CrossRefPubMedPubMedCentral Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: Twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10:405–12.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Dizon DS, Graham D, Thompson MA, et al. Practical guidance: the use of social media in oncology practice. J oncol prac / Am Soc Clin Oncol. 2012;8:e114–24.CrossRef Dizon DS, Graham D, Thompson MA, et al. Practical guidance: the use of social media in oncology practice. J oncol prac / Am Soc Clin Oncol. 2012;8:e114–24.CrossRef
6.
Zurück zum Zitat Markham MJ, Gentile D, Graham DL. Social media for networking, professional development, and patient engagement. Am Soc Clin Oncol educ book / ASCO Am Soc Clin Oncol Meeting. 2017;37:782–7.CrossRef Markham MJ, Gentile D, Graham DL. Social media for networking, professional development, and patient engagement. Am Soc Clin Oncol educ book / ASCO Am Soc Clin Oncol Meeting. 2017;37:782–7.CrossRef
8.
Zurück zum Zitat Sedrak MS, Dizon DS, Anderson PF, et al. The emerging role of professional social media use in oncology. Future Oncol. 2017;13:1281–5.CrossRefPubMed Sedrak MS, Dizon DS, Anderson PF, et al. The emerging role of professional social media use in oncology. Future Oncol. 2017;13:1281–5.CrossRefPubMed
9.
Zurück zum Zitat Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the Twitter discussion on urologic oncology. Urologic oncology 2016. Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the Twitter discussion on urologic oncology. Urologic oncology 2016.
13.
Zurück zum Zitat Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520. Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520.
15.
Zurück zum Zitat Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)—focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRefPubMed Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)—focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRefPubMed
16.
Zurück zum Zitat Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRefPubMed Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRefPubMed
17.
Zurück zum Zitat Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782. 4-5, 91 Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782. 4-5, 91
19.
Zurück zum Zitat Sinnenberg L, DiSilvestro CL, Mancheno C, et al. Twitter as a potential data source for cardiovascular disease research. JAMA cardiology. 2016;1:1032–6.CrossRefPubMed Sinnenberg L, DiSilvestro CL, Mancheno C, et al. Twitter as a potential data source for cardiovascular disease research. JAMA cardiology. 2016;1:1032–6.CrossRefPubMed
20.
Zurück zum Zitat Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the use and impact of Twitter during American Society of Clinical Oncology annual meetings from 2011 to 2016: focus on advanced metrics and user trends. J oncol prac / Am Soc Clin Oncol. 2017;13:e623–e31.CrossRef Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the use and impact of Twitter during American Society of Clinical Oncology annual meetings from 2011 to 2016: focus on advanced metrics and user trends. J oncol prac / Am Soc Clin Oncol. 2017;13:e623–e31.CrossRef
21.
Zurück zum Zitat Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in Twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J oncol pract / Am Soc Clin Oncol. 2012;8:173–8.CrossRef Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in Twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J oncol pract / Am Soc Clin Oncol. 2012;8:173–8.CrossRef
Metadaten
Titel
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM
verfasst von
Naveen Pemmaraju
Audun Utengen
Vikas Gupta
Jean-Jacques Kiladjian
Ruben Mesa
Michael A. Thompson
Publikationsdatum
06.11.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0421-y

Weitere Artikel der Ausgabe 6/2017

Current Hematologic Malignancy Reports 6/2017 Zur Ausgabe

Acute Myeloid Leukemias (H Erba, Section Editor)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Measurement of Residual Disease in Acute Myeloid Leukemia

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?

CART and Immunotherapy (M Ruella, Section Editor)

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Myelodysplastic Syndromes (M Savona, Section Editor)

Models of Prognostication in Chronic Myelomonocytic Leukemia

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.